Patent details

EP3419623 Title: METHODS FOR USING FXR AGONISTS

  • Data
  • Documents

Basic Information

Publication number:
EP3419623
PCT Application Number:
IB2017050912
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP177079597
PCT Publication Number:
WO2017145031
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
METHODS FOR USING FXR AGONISTS
French Title of Invention:
PROCÉDÉS D'UTILISATION D'AGONISTES DE FXR
German Title of Invention:
VERFAHREN ZUR VERWENDUNG VON FXR-AGONISTEN
SPC Number:

Dates

Filing date:
17/02/2017
Grant date:
29/09/2021
EP Publication Date:
02/01/2019
PCT Publication Date:
31/08/2017
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
29/09/2021
EP B1 Publication Date:
29/09/2021
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
17/02/2022
Expiration date:
17/02/2037
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
22/09/2021
 
 

Name:
Novartis AG
Address:
Lichtstrasse 35, 4056 Basel, Switzerland (CH)

Inventor

1

Name:
LAFFITTE, Bryan
Address:
United States (US)

2

Name:
CHEN, Jin
Address:
United States (US)

3

Name:
BADMAN, Michael
Address:
United States (US)

4

Name:
LINDGREN, Sam
Address:
Switzerland (CH)

Priority

1

Priority Number:
201662298117 P
Priority Date:
22/02/2016
Priority Country:
United States (US)

2

Priority Number:
201662420702 P
Priority Date:
11/11/2016
Priority Country:
United States (US)

Classification

IPC classification:
A61K 31/46; A61P 1/00; A61P 1/16; A61K 31/4748; A61K 31/497; A61K 31/506;

Publication

European Patent Bulletin

Issue number:
202139
Publication date:
29/09/2021
Description:
Grant (B1)
Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer: